NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Last update: 01 Dec, 2:04PM

106.80

0.67 (0.63%)

  • 1D 0.63%
  • 5D -1.67%
  • 1M 1.66%
  • 6M -24.94%
  • YTD 4.59%
  • 1Y 3.98%
  • 5Y 270.45%
Previous Close 106.13
Open 105.43
Volume 2,215,240
Avg. Volume (3M) 4,887,198
Market Cap 464,527,687,680
Price / Earnings (TTM) 35.60
Price / Earnings (Forward) 26.39
Price / Sales 12.14
Price / Book 27.10
52 Weeks Range
94.73 (-11%) — 148.15 (38%)
Earnings Date 5 Feb 2025
TTM Dividend Yield 1.35%
Profit Margin 35.01%
Operating Margin (TTM) 47.43%
Diluted EPS (TTM) 2.98
Quarterly Revenue Growth (YOY) 21.40%
Quarterly Earnings Growth (YOY) 21.50%
Total Debt/Equity (MRQ) 47.27%
Current Ratio (MRQ) 0.940
Operating Cash Flow (TTM) 118.22 B
Levered Free Cash Flow (TTM) 46.04 B
Return on Assets (TTM) 21.47%
Return on Equity (TTM) 88.73%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Novo Nordisk A/S Bearish Bullish

AIStockmoo Score

1.5
Analyst Consensus 3.0
Insider Activity NA
Price Volatility 4.5
Technical Moving Averages -1.0
Technical Oscillators -0.5
Average 1.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NVO 465 B 1.35% 35.60 27.10
ADCT 190 M - - -
BHVN 4 B - - 11.75
RCUS 1 B - - 2.46
DNA 579 M - - 0.780
NUVB 946 M - - 1.80

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector Healthcare
Industry Biotechnology
Investment Style Large Growth
% Held by Institutions 10.16%

Ownership

Name Date Shares Held
Everett Harris & Co /Ca/ 30 Sep 2024 6,438,614
52 Weeks Range
94.73 (-11%) — 148.15 (38%)
Price Target Range
156.00 (46%) — 160.00 (49%)
High 160.00 (Cantor Fitzgerald, 49.81%) Buy
Median 158.00 (47.94%)
Low 156.00 (BMO Capital, 46.07%) Buy
Average 158.00 (47.94%)
Total 2 Buy
Avg. Price @ Call 111.79
Firm Date Target Price Call Price @ Call
Cantor Fitzgerald 06 Nov 2024 160.00 (49.81%) Buy 105.36
10 Oct 2024 160.00 (49.81%) Buy 117.53
BMO Capital 17 Oct 2024 156.00 (46.07%) Buy 118.22

No data within this time range.

  • 3M
Date Type Details
20 Dec 2024 CNBC FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
20 Dec 2024 Announcement Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
18 Dec 2024 Announcement The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
18 Dec 2024 CNBC Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
16 Dec 2024 Announcement Novo Nordisk A/S - share repurchase programme
16 Dec 2024 Announcement Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
14 Dec 2024 Announcement Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
12 Dec 2024 Announcement Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
11 Dec 2024 CNBC Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
09 Dec 2024 CNBC Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
06 Dec 2024 Announcement The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
04 Dec 2024 CNBC Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
03 Dec 2024 Announcement Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk
26 Nov 2024 CNBC Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
25 Nov 2024 Announcement Novo Nordisk A/S - share repurchase programme
13 Nov 2024 CNBC Amgen says no concerns around weight loss drug’s bone density data after stock falls
08 Nov 2024 Announcement Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 Nov 2024 Announcement Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
07 Nov 2024 Announcement Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06 Nov 2024 Announcement Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
05 Nov 2024 Announcement Novo Nordisk A/S - share repurchase programme
01 Nov 2024 Announcement Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
30 Oct 2024 CNBC Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
30 Oct 2024 CNBC Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
23 Oct 2024 CNBC Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
21 Oct 2024 Announcement Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
21 Oct 2024 Announcement Novo Nordisk A/S - share repurchase programme
18 Oct 2024 Announcement Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
08 Oct 2024 Announcement Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
07 Oct 2024 Announcement Novo Nordisk A/S – Share repurchase programme
25 Sep 2024 CNBC Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
24 Sep 2024 CNBC 'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricing
21 Sep 2024 CNBC FTC sues drug middlemen for allegedly inflating insulin prices
Show more
TTM Dividend Yield 1.35%
5Y Average Dividend Yield 2.99%
Payout Ratio 46.73%
Expected Next Dividend Payment Apr 2025
Ex Date Announcement Date Payment Date Details
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Cash
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Cash
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Cash
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Cash
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Cash
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Cash
16 Aug 2021 - 25 Aug 2021 0.5502889 Cash
26 Mar 2021 - 07 Apr 2021 0.922122 Cash
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Cash
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Cash
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Cash
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Cash
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Cash
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Cash
17 Aug 2017 - 29 Aug 2017 0.33589 Cash
23 Mar 2017 - 04 Apr 2017 0.479369 Cash
11 Aug 2016 - 23 Aug 2016 0.331026 Cash
18 Mar 2016 - 30 Mar 2016 0.69943 Cash
19 Mar 2015 - 31 Mar 2015 0.532885 Cash
21 Mar 2014 - 02 Apr 2014 0.606122 Cash
21 Mar 2013 - 02 Apr 2013 2.264307 Cash
22 Mar 2012 - 03 Apr 2012 1.831902 Cash
24 Mar 2011 - 05 Apr 2011 1.357901 Cash
25 Mar 2010 - 07 Apr 2010 0.978615 Cash
19 Mar 2009 - 31 Mar 2009 0.781532 Cash
13 Mar 2008 - 25 Mar 2008 0.678462 Cash
08 Mar 2007 - 20 Mar 2007 0.891779 Cash
09 Mar 2006 - 21 Mar 2006 0.691753 Cash
10 Mar 2005 - 22 Mar 2005 0.61725 Cash
17 Mar 2004 - 29 Mar 2004 0.52096 Cash
26 Mar 2003 - 07 Apr 2003 0.37647 Cash
13 Mar 2002 - 25 Mar 2002 0.2848 Cash
21 Mar 2001 - 02 Apr 2001 0.5681 Cash
24 Mar 2000 - 06 Apr 2000 0.4672 Cash
25 Mar 1999 - 06 Apr 1999 0.4182 Cash
27 Mar 1998 - 08 Apr 1998 0.3051 Cash
25 Apr 1997 - 07 May 1997 0.239 Cash
01 May 1996 - 14 May 1996 0.1806 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 1.44 2 1.35
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria